Testicular Cancer (Germ Cell Carcinoma)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    KIT Mutation 10% Imatinib (KIT/PDGFR/BCR-ABL inhibitor):
    • Phase 2: 5/6 pts with KIT+ per IHC had PD; 1 pt had SD with a >50% decline in serum AFP for 3 mo before developing PD (1)
    PD-1/PD-L1 N/A N/A Nivolumab (PD-1 inhibitor):
    • Case report: Response observed in pt with embryonal carcinoma (2)
    Other topics in Targets by Organ Site